While the immune milieu has been suggested to influence T-DM1 therapy as mentioned above, the correlation of TILs with pathologic complete response in preoperative chemotherapy with trastuzumab and pertuzumab in patients with HER2-positive breast cancer suggests that antitumor immunity is also important for treatment outcomes [8, 9]. The gene discussed is ERBB2; the disease is breast cancer.